SCM
CRXTW

Shaolin Capital Management’s Clarus Therapeutics Holdings, Inc. Warrants CRXTW Stock Holding History

Shaolin Capital Management’s Portfolio CRXTW Stock Details CRXTW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-100,823
Closed -$76K – 640
2021
Q2 		$76K Buy
+100,823
New +$63.2K ﹤0.01% 503

Other funds holding CRXTW

LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return
RCM
Radcliffe Capital Management Bala Cynwyd, Pennsylvania $1.32B AUM 1.82% 1-Year Est. Return
CH
CVI Holdings Wilmington, Delaware $116M AUM 5.68% 1-Year Est. Return
AC
Aristeia Capital Greenwich, Connecticut $7.69B AUM 15.48% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
YCM
Yakira Capital Management Westport, Connecticut $351M AUM 21.82% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $21.5B AUM 81.81% 1-Year Est. Return
WAM
Warberg Asset Management Winnetka, Illinois $551M AUM 34.68% 1-Year Est. Return
CCM
Context Capital Management Lajolla, California $5.15B AUM 1.28% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return

Shaolin Capital Management's CRXTW Position: Q3 2021 in Review

Shaolin Capital Management sold out of Clarus Therapeutics Holdings, Inc. Warrants (CRXTW) in Q3 2021, closing a stake of 100,823 shares — an estimated $76K sold.

Shaolin Capital Management first reported a position in CRXTW in Q2 2021 and held it in 1 quarter. The position peaked at $76K in Q2 2021. 22 funds tracked by Wall St. Rank hold CRXTW as of Q3 2021.

  • Shaolin Capital Management reported no remaining Clarus Therapeutics Holdings, Inc. Warrants position as of Q3 2021 after selling out during the quarter.
  • Shaolin Capital Management sold 100,823 Clarus Therapeutics Holdings, Inc. Warrants shares in Q3 2021, an estimated $76K.
  • Shaolin Capital Management first reported a position in Clarus Therapeutics Holdings, Inc. Warrants in Q2 2021 and held it in 1 quarter.
  • Shaolin Capital Management's Clarus Therapeutics Holdings, Inc. Warrants position peaked at $76K in Q2 2021.
  • 22 funds tracked by Wall St. Rank held Clarus Therapeutics Holdings, Inc. Warrants as of Q3 2021.

Based on Shaolin Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.